RxDoctor Payments Data

Laura Green, MD

Ophthalmology · Baltimore, MDNPI 1255382263

Payments from drug & device makers

$1,225in general payments, 2019–2025

Across 45 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$199
  • Sun Pharmaceutical Industries Inc.$159
  • Bausch & Lomb Americas Inc.$158
  • Shire North American Group Inc$123
  • Alcon$120
  • Dompe US, Inc.$85
  • plus $382 from 10 others

What the payments were for

  • Food & beverage$1,225100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,225 in reported general payments places this provider in the 45th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$291,129
Medicare patients
985
Services billed
2,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine79$92,547
XiidraLifitegrast78$86,873
TyrvayaVarenicline Tartrate29$23,577
MieboPerfluorohexyloctane/Pf16$18,454
Cyclosporine38$17,890
Tobramycin-DexamethasoneTobramycin/Dexamethasone96$4,732
Prednisolone Acetate89$4,253
TobradexTobramycin/Dexamethasone14$3,721
Latanoprost130$2,055
Fluorometholone23$1,748
Doxycycline Monohydrate36$1,201
Epinastine Hcl13$981
Timolol Maleate52$978
Ketorolac Tromethamine21$725
Doxycycline Hyclate31$675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$158$105,32794 claims
Oyster Point Pharma, Inc.Tyrvaya$57$23,57729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →